ScripAfter a recent series B round, Beacon Therapeutics has boosted its finances by $170m, bringing its total funding to date to $290m, as it looks to advance in the crowded field of gene therapies for t
ScripKeeping with the trend of combining companies to help financially constrained biotechs stay afloat, investment major Syncona has again come to the rescue of Freeline Therapeutics Holdings PLC and me
ScripSyncona Limited-backed Beacon Therapeutics has launched with a £96m ($120m) series A fundraise and a pipeline of candidates for unaddressed retinal conditions – including a Phase II asset – in a bid
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OrsoBio Splurges With Four Concurrent L